Neumora Therapeutics (NMRA) Shares Outstanding (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Shares Outstanding (Entity) of $182.2 million for Q1 2026, up 12.62% year-over-year from $161.7 million in Q1 2025, and up 4.53% quarter-over-quarter from $174.3 million in Q4 2025.
Neumora Therapeutics (NMRA) Shares Outstanding (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Shares Outstanding (Entity) history runs 5 years deep, the most recent figure standing at $182.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 12.62% year-over-year to $182.2 million; the TTM figure through Mar 2026 stood at $182.2 million (up 12.62% YoY), while the FY2025 annual figure was $174.3 million, up 7.76% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $182.2 million, up from $174.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $182.2 million in Q1 2026, with the low at $32.6 million in Q3 2022.
- The 5-year median for Shares Outstanding (Entity) is $160.0 million (2024), against an average of $115.1 million.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) soared 387.33% in 2024, then gained 0.91% in 2025.
- Neumora Therapeutics' Shares Outstanding (Entity) stood at $32.6 million in 2022, then surged by 99.38% to $65.0 million in 2023, then soared by 148.7% to $161.7 million in 2024, then rose by 7.76% to $174.3 million in 2025, then climbed by 4.53% to $182.2 million in 2026.
- Business Quant data shows NMRA's Shares Outstanding (Entity) at $182.2 million in Q1 2026, $174.3 million in Q4 2025, and $161.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 179.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179.87 Mn |
| Dec 31, 2025 | 163.39 Mn |
| Sep 30, 2025 | 161.84 Mn |
| Jun 30, 2025 | 161.69 Mn |
| Mar 31, 2025 | 161.45 Mn |
| Dec 31, 2024 | 159.38 Mn |
| Sep 30, 2024 | 159.58 Mn |
| Jun 30, 2024 | 158.98 Mn |
| Mar 31, 2024 | 157.94 Mn |
| Dec 31, 2023 | 65.02 Mn |
| Sep 30, 2023 | 46.69 Mn |
| Jun 30, 2023 | 30.13 Mn |
| Mar 31, 2023 | 29.28 Mn |
| Dec 31, 2022 | 27.21 Mn |
| Sep 30, 2022 | 27.65 Mn |